COMPASS Pathways plc (NASDAQ:CMPS) Expected to Post Earnings of -$0.68 Per Share

Brokerages predict that COMPASS Pathways plc (NASDAQ:CMPSGet Rating) will announce earnings of ($0.68) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for COMPASS Pathways’ earnings, with the highest EPS estimate coming in at ($0.65) and the lowest estimate coming in at ($0.73). COMPASS Pathways posted earnings per share of ($0.35) in the same quarter last year, which suggests a negative year over year growth rate of 94.3%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that COMPASS Pathways will report full-year earnings of ($2.85) per share for the current financial year, with EPS estimates ranging from ($3.02) to ($2.69). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.37) per share, with EPS estimates ranging from ($3.69) to ($3.04). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for COMPASS Pathways.

COMPASS Pathways (NASDAQ:CMPSGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same period last year, the business posted ($0.52) EPS.

Several research analysts have recently issued reports on CMPS shares. Zacks Investment Research cut COMPASS Pathways from a “hold” rating to a “sell” rating in a research note on Tuesday, March 1st. Canaccord Genuity Group reduced their price target on shares of COMPASS Pathways from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Monday, February 28th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $74.89.

In other news, insider Ekaterina Malievskaia sold 6,372 shares of the firm’s stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $12.48, for a total transaction of $79,522.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David Y. Norton sold 3,384 shares of COMPASS Pathways stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total value of $42,232.32. The disclosure for this sale can be found here.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP acquired a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $799,000. AGF Investments Inc. grew its position in shares of COMPASS Pathways by 937,652.9% in the third quarter. AGF Investments Inc. now owns 637,672 shares of the company’s stock valued at $19,047,000 after purchasing an additional 637,604 shares during the period. Royal Bank of Canada increased its stake in shares of COMPASS Pathways by 7.8% during the second quarter. Royal Bank of Canada now owns 6,648 shares of the company’s stock worth $253,000 after purchasing an additional 482 shares in the last quarter. Pekin Hardy Strauss Inc. purchased a new position in COMPASS Pathways in the 3rd quarter valued at about $439,000. Finally, TAP Consulting LLC acquired a new stake in COMPASS Pathways in the 4th quarter worth about $44,000. 17.86% of the stock is currently owned by institutional investors.

COMPASS Pathways stock traded up $0.20 during trading hours on Friday, hitting $12.65. 1,011 shares of the stock traded hands, compared to its average volume of 314,951. The firm’s 50 day moving average price is $13.41 and its 200-day moving average price is $22.99. The stock has a market capitalization of $531.55 million, a price-to-earnings ratio of -6.99 and a beta of 3.34. COMPASS Pathways has a 1 year low of $10.50 and a 1 year high of $49.51.

COMPASS Pathways Company Profile (Get Rating)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.

See Also

Get a free copy of the Zacks research report on COMPASS Pathways (CMPS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with's FREE daily email newsletter.